KALA
KALA BIO, Inc.
There isn't enough reported data to score KALA yet.
KALA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
KALA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
KALA PE Valuation
KALA has no meaningful PE right now: it lost money over the past year.
KALA Forward outlook
There aren't enough analyst estimates for KALA to show an outlook.
KALA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$204.63 | +$302.87 |
| Q3 2025 | -$252.50 | +$341.50 |
| Q2 2025 | -$295.50 | +$372.50 |
| Q1 2025 | -$368.00 | +$360.00 |
| Q4 2024 | -$507.50 | +$360.00 |
| Q3 2022 | -$2,862.50 | +$2,237.50 |
| Q2 2022 | -$4,900.00 | +$375.00 |
| Q1 2022 | -$5,375.00 | -$475.00 |
KALA is still losing money, but far less than before: $204.63 per share over the past year, against $7,225.00 at its worst in late 2019.
KALA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $420K | -86% |
| Q2 2022 | $2.1M | -31% |
| Q1 2022 | $1.4M | -58% |
| Q4 2021 | $1.9M | -17% |
| Q3 2021 | $3.1M | +38% |
| Q2 2021 | $3.1M | +266% |
| Q1 2021 | $3.3M | +205% |
| Q4 2020 | $2.2M | +90% |
KALA's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -3469% | -2619 points |
| Q2 2022 | -1237% | -285 points |
| Q1 2022 | -2253% | -1386 points |
| Q4 2021 | -2522% | -1227 points |
| Q3 2021 | -850% | +314 points |
| Q2 2021 | -952% | +1603 points |
| Q1 2021 | -867% | +1012 points |
| Q4 2020 | -1295% | +417 points |
KALA's operating margin was −3469% last quarter, down 2619 points from the same quarter a year ago, near the bottom of its range since 2019.
KALA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.5M | +$15M |
| Q1 2026 | -$2.9M | +$5.9M |
| Q4 2025 | -$4.6M | +$42K |
| Q3 2025 | -$10.9M | -$6.2M |
| Q2 2025 | -$16.6M | -$7.3M |
| Q1 2025 | -$8.8M | +$2M |
| Q4 2024 | -$4.6M | +$3.1M |
| Q3 2024 | -$4.7M | -$1.8M |
KALA has burned cash in almost every quarter: −$20M over the past year, against −$35M the year before.
KALA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -54% | -88.8K shares |
| 1 year | -42% | -52.8K shares |
| 3 years | +145% | +44K shares |
| 5 years | +231% | +51.7K shares |
| Available history | +443% | +60.5K shares |
KALA has 74,159 diluted shares, down 42% from a year ago.
KALA Net Leverage
KALA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
KALA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 4.7 | Oversold |
KALA's weekly RSI is 33 (neutral) and its Stochastic is 5 (oversold).
KALA PE vs Healthcare Sector
KALA has no meaningful PE right now: it lost money over the past year.
KALA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.25 | 36% below |
| 20 week MA | $0.59 | 73% below |
| 50 week MA | $9.99 | 98% below |
| 100 week MA | $160.4 | 100% below |
| 200 week MA | $321.9 | 100% below |
KALA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
KALA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9,325.0 | $19,150.0 | +105% |
| 2021 | $19,150.0 | $3,400.0 | -82% |
| 2022 | $3,400.0 | $194.0 | -94% |
| 2023 | $194.0 | $350.0 | +80% |
| 2024 | $350.0 | $349.0 | -0.3% |
| 2025 | $349.0 | $32.5 | -91% |
| 2026 YTD | $32.5 | $0.16 | -100% |
KALA's yearly returns have swung widely, from +105% in 2020 to −94% in 2022. It's down 100% so far in 2026.